Making Critical Oncology Decisions Before the Data Fully Mature

In oncology drug development, critical development and regulatory decisions are often required before overall survival data have fully matured. Interim analyses can provide early insight, but treatment effects and potential harm signals may change as additional survival events accumulate.

MMS partnered with Friends of Cancer Research and participating stakeholders to develop a more systematic, data-driven approach for evaluating immature overall survival data.

Using advanced simulation methodologies, statistical expertise, and KerusCloud®, MMS helped create realistic oncology trial scenarios to quantify uncertainty and evaluate how early efficacy or harm signals could evolve over time.

What You’ll Learn

• Discover how advanced survival data analytics can improve interpretation of immature overall survival results.
• Learn how simulation can quantify uncertainty around early efficacy and harm signals. See how KerusCloud® supports evidence generation and statistical decision-making.
• Understand how data-driven frameworks can provide greater transparency and consistency in evaluating interim findings.
• Explore how advanced analytics can support oncology clinical development and regulatory strategy.